Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Tohoku J Exp Med ; 258(1): 63-68, 2022 Aug 10.
Article in English | MEDLINE | ID: covidwho-1938489

ABSTRACT

The detailed clinical course of coronavirus disease 2019 (COVID-19) in patients with hairy cell leukemia (HCL) is rarely reported. We report the first case of HCL diagnosed with prolonged pancytopenia after COVID-19 infection in Japan. We describe the case of a 56-year-old man who was diagnosed with COVID-19. Computed tomography revealed ground-glass opacities in the bilateral lung lobes as well as splenomegaly. Remdesivir and dexamethasone were administered for the treatment of COVID-19. Since the pancytopenia persisted, bone marrow examination was performed, and he was diagnosed with HCL. Although pancytopenia can occur with COVID-19 alone, clinicians should be alerted regarding the presence of hematologic malignancies in patients in whom pancytopenia persists after COVID-19 treatment or in those with splenomegaly. Further, the condition of all previously reported patients with COVID-19 associated with HCL was severe enough to require mechanical ventilation. This is the first case in which the disease was not severe. The interleukin-6 (IL-6) level was lower in this case than in previous cases, suggesting that racial differences in IL-6 production may have contributed to COVID-19 severity.


Subject(s)
COVID-19 , Coronavirus , Leukemia, Hairy Cell , Pancytopenia , COVID-19/complications , COVID-19/drug therapy , Humans , Interleukin-6 , Leukemia, Hairy Cell/complications , Leukemia, Hairy Cell/drug therapy , Leukemia, Hairy Cell/pathology , Male , Middle Aged , Pancytopenia/complications , Splenomegaly/complications , Splenomegaly/pathology
2.
Curr Opin Oncol ; 33(5): 412-419, 2021 09 01.
Article in English | MEDLINE | ID: covidwho-1364850

ABSTRACT

PURPOSE OF REVIEW: This article provides a brief update on the recommended diagnosis and treatment strategies for patients with the classic form of hairy cell leukemia (HCL) and HCL variant (HCLv). RECENT FINDINGS: HCL is a chronic B-cell malignancy with multiple treatment options. In recent years, many novel drugs have been assessed for HCL treatment with promising results. The investigated nonchemotherapy options include moxetumomab pasudotox, which targets CD22; vemurafenib or dabrafenib, which target the BRAFV600E protein; trametinib, which targets mitogen-activated protein kinase enzyme; and ibrutinib, which targets Bruton tyrosine kinase. SUMMARY: Purine analogs significantly improve survival in patients with HCL. However, patients often relapse, require multiple treatments, and may become refractory. The introduction of novel agents has expanded the spectrum of therapy possibilities in those patients. In the coming years, they will assist standard therapy for patients with HCL who may currently have suboptimal results.


Subject(s)
Antineoplastic Agents , Leukemia, Hairy Cell , Antineoplastic Agents/therapeutic use , Humans , Leukemia, Hairy Cell/drug therapy , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL